Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deep Brain Stimulation | 8 | 2017 | 40 | 1.560 |
Why?
|
| Electrodes, Implanted | 3 | 2017 | 22 | 0.540 |
Why?
|
| Parkinson Disease | 12 | 2013 | 640 | 0.500 |
Why?
|
| Anterior Thalamic Nuclei | 2 | 2010 | 3 | 0.370 |
Why?
|
| Epilepsy | 2 | 2010 | 68 | 0.350 |
Why?
|
| Ventral Thalamic Nuclei | 2 | 2017 | 2 | 0.340 |
Why?
|
| Genetic Therapy | 6 | 2014 | 84 | 0.330 |
Why?
|
| Dentate Gyrus | 1 | 2009 | 6 | 0.330 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2009 | 30 | 0.320 |
Why?
|
| Brain | 5 | 2017 | 1569 | 0.310 |
Why?
|
| Essential Tremor | 1 | 2008 | 5 | 0.300 |
Why?
|
| Neurons | 3 | 2009 | 332 | 0.290 |
Why?
|
| Hypothalamic Area, Lateral | 1 | 2007 | 2 | 0.280 |
Why?
|
| Dependovirus | 3 | 2014 | 39 | 0.260 |
Why?
|
| Postoperative Complications | 2 | 2009 | 901 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 1059 | 0.240 |
Why?
|
| Obesity | 1 | 2007 | 297 | 0.230 |
Why?
|
| Neurturin | 3 | 2010 | 22 | 0.220 |
Why?
|
| Stereotaxic Techniques | 4 | 2017 | 15 | 0.220 |
Why?
|
| Adrenal Medulla | 4 | 1997 | 7 | 0.210 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 368 | 0.200 |
Why?
|
| Genetic Vectors | 4 | 2014 | 57 | 0.180 |
Why?
|
| Transplantation, Heterotopic | 3 | 1997 | 7 | 0.170 |
Why?
|
| Caudate Nucleus | 3 | 1997 | 11 | 0.170 |
Why?
|
| Nerve Growth Factor | 2 | 2014 | 43 | 0.160 |
Why?
|
| Putamen | 2 | 2010 | 19 | 0.160 |
Why?
|
| Male | 15 | 2017 | 14277 | 0.160 |
Why?
|
| Postoperative Period | 3 | 2017 | 325 | 0.140 |
Why?
|
| Humans | 19 | 2017 | 25967 | 0.140 |
Why?
|
| Peripheral Nerves | 1 | 1997 | 17 | 0.140 |
Why?
|
| Globus Pallidus | 3 | 2017 | 10 | 0.140 |
Why?
|
| Middle Aged | 10 | 2017 | 8772 | 0.140 |
Why?
|
| Corpus Striatum | 3 | 2008 | 65 | 0.130 |
Why?
|
| Follow-Up Studies | 7 | 2010 | 1757 | 0.130 |
Why?
|
| Dopamine | 3 | 2007 | 82 | 0.130 |
Why?
|
| Nerve Growth Factors | 2 | 2010 | 37 | 0.130 |
Why?
|
| Substantia Nigra | 3 | 2007 | 119 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2015 | 3399 | 0.120 |
Why?
|
| Animals | 8 | 2013 | 3503 | 0.120 |
Why?
|
| Female | 12 | 2017 | 14734 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 2 | 2009 | 153 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2012 | 252 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2014 | 210 | 0.120 |
Why?
|
| Movement Disorders | 1 | 2015 | 66 | 0.110 |
Why?
|
| Parkinsonian Disorders | 2 | 2009 | 213 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 649 | 0.110 |
Why?
|
| Adult | 7 | 2015 | 7662 | 0.110 |
Why?
|
| Disease Models, Animal | 4 | 2013 | 577 | 0.110 |
Why?
|
| Electric Stimulation Therapy | 2 | 2010 | 39 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 648 | 0.110 |
Why?
|
| Colon | 1 | 2013 | 111 | 0.100 |
Why?
|
| Intraoperative Period | 1 | 2012 | 24 | 0.100 |
Why?
|
| Skull | 1 | 2012 | 19 | 0.100 |
Why?
|
| alpha-Synuclein | 1 | 2013 | 119 | 0.100 |
Why?
|
| Observer Variation | 1 | 2012 | 97 | 0.090 |
Why?
|
| Cell Count | 2 | 2009 | 80 | 0.090 |
Why?
|
| Microelectrodes | 2 | 2009 | 18 | 0.090 |
Why?
|
| Functional Laterality | 2 | 2010 | 61 | 0.090 |
Why?
|
| Subthalamic Nucleus | 2 | 2017 | 19 | 0.080 |
Why?
|
| Radiography | 1 | 2012 | 616 | 0.080 |
Why?
|
| Antiparkinson Agents | 2 | 2002 | 42 | 0.080 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2009 | 5 | 0.080 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2009 | 9 | 0.080 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2009 | 9 | 0.080 |
Why?
|
| Cell Survival | 1 | 2009 | 116 | 0.080 |
Why?
|
| Pyramidal Cells | 1 | 2009 | 35 | 0.080 |
Why?
|
| Blepharospasm | 1 | 2009 | 1 | 0.080 |
Why?
|
| Torticollis | 1 | 2009 | 7 | 0.080 |
Why?
|
| Transgenes | 1 | 2008 | 10 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 92 | 0.070 |
Why?
|
| Medical Records | 1 | 2008 | 31 | 0.070 |
Why?
|
| Alzheimer Disease | 2 | 2014 | 2036 | 0.070 |
Why?
|
| Tyrosine 3-Monooxygenase | 4 | 2013 | 52 | 0.070 |
Why?
|
| Drinking | 1 | 2007 | 6 | 0.070 |
Why?
|
| Eating | 1 | 2007 | 48 | 0.070 |
Why?
|
| Aged | 5 | 2015 | 8732 | 0.070 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2007 | 10 | 0.070 |
Why?
|
| MPTP Poisoning | 1 | 2007 | 15 | 0.070 |
Why?
|
| Neostriatum | 1 | 2007 | 14 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 320 | 0.070 |
Why?
|
| Autopsy | 1 | 2008 | 334 | 0.070 |
Why?
|
| Inflammation | 1 | 2008 | 267 | 0.060 |
Why?
|
| Rats | 1 | 2007 | 640 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 1997 | 297 | 0.060 |
Why?
|
| Motor Activity | 3 | 2010 | 317 | 0.060 |
Why?
|
| Cholinergic Fibers | 1 | 2005 | 9 | 0.060 |
Why?
|
| Prosencephalon | 1 | 2005 | 8 | 0.060 |
Why?
|
| Brain Tissue Transplantation | 2 | 1997 | 15 | 0.060 |
Why?
|
| Fetal Tissue Transplantation | 2 | 1997 | 22 | 0.060 |
Why?
|
| Adolescent | 1 | 2009 | 2099 | 0.050 |
Why?
|
| Young Adult | 1 | 2009 | 1941 | 0.050 |
Why?
|
| Phonation | 1 | 2003 | 4 | 0.050 |
Why?
|
| Speech Disorders | 1 | 2003 | 10 | 0.050 |
Why?
|
| Speech | 1 | 2003 | 21 | 0.050 |
Why?
|
| Respiration | 1 | 2003 | 30 | 0.050 |
Why?
|
| Electric Stimulation | 1 | 2003 | 50 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 868 | 0.040 |
Why?
|
| Aging | 2 | 2007 | 1483 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 84 | 0.040 |
Why?
|
| Registries | 2 | 1991 | 192 | 0.040 |
Why?
|
| Transplantation, Autologous | 2 | 1997 | 156 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2010 | 393 | 0.040 |
Why?
|
| Time Factors | 2 | 2013 | 1391 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 30 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 28 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2017 | 42 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2007 | 58 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 2 | 2010 | 26 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2014 | 1150 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 193 | 0.030 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2014 | 10 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2013 | 11 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2013 | 10 | 0.030 |
Why?
|
| Vagus Nerve | 1 | 2013 | 14 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 10 | 0.030 |
Why?
|
| Permeability | 1 | 2013 | 96 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1993 | 10 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 240 | 0.030 |
Why?
|
| Thalamus | 1 | 1993 | 15 | 0.030 |
Why?
|
| Mesencephalon | 1 | 1993 | 23 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 408 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 143 | 0.020 |
Why?
|
| Chromogranins | 1 | 1991 | 3 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 655 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1991 | 11 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2010 | 14 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 1352 | 0.020 |
Why?
|
| Dysarthria | 1 | 2009 | 2 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2009 | 16 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 210 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 99 | 0.020 |
Why?
|
| Motor Skills | 1 | 2009 | 45 | 0.020 |
Why?
|
| Memory Disorders | 1 | 2010 | 154 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2008 | 25 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 143 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2009 | 145 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 13 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2006 | 9 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 2006 | 14 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2007 | 47 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 29 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2006 | 61 | 0.020 |
Why?
|
| Depression | 1 | 2010 | 412 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1333 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2005 | 6 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2006 | 299 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 56 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 36 | 0.010 |
Why?
|
| Speech Articulation Tests | 1 | 2003 | 3 | 0.010 |
Why?
|
| Acoustics | 1 | 2003 | 17 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 2003 | 46 | 0.010 |
Why?
|
| Lentivirus | 1 | 2002 | 7 | 0.010 |
Why?
|
| Haplorhini | 1 | 2002 | 8 | 0.010 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2002 | 18 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 2002 | 11 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 55 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 72 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 390 | 0.010 |
Why?
|
| Cognition | 1 | 2005 | 1250 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1997 | 278 | 0.010 |
Why?
|
| Data Collection | 1 | 1991 | 89 | 0.010 |
Why?
|
| Chromogranin A | 1 | 1991 | 8 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1990 | 9 | 0.010 |
Why?
|
| Canada | 1 | 1990 | 45 | 0.010 |
Why?
|
| Levodopa | 1 | 1990 | 34 | 0.010 |
Why?
|
| Prognosis | 1 | 1991 | 784 | 0.000 |
Why?
|
| Chicago | 1 | 1990 | 898 | 0.000 |
Why?
|
| United States | 1 | 1990 | 1989 | 0.000 |
Why?
|